Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LABTRUST, LLC

NPI: 1629374335 · COVINGTON, LA 70433 · Clinical Medical Laboratory · NPI assigned 01/28/2011

$1.45M
Total Medicaid Paid
49,535
Total Claims
40,185
Beneficiaries
36
Codes Billed
2018-01
First Month
2021-08
Last Month

Provider Details

Authorized OfficialPARKINS, KEVIN (PRESIDENT)
NPI Enumeration Date01/28/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 7,229 $29K
2019 29,338 $659K
2020 7,294 $448K
2021 5,674 $314K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 6,758 5,075 $565K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 5,099 2,687 $272K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 6,609 5,236 $258K
80346 1,638 1,472 $24K
80358 1,522 1,367 $19K
80359 1,462 1,309 $18K
80348 1,410 1,258 $18K
80373 1,269 1,130 $17K
83992 1,429 1,277 $17K
80372 1,172 1,036 $15K
80368 1,078 956 $15K
80323 1,761 949 $15K
80336 873 799 $14K
80354 1,113 983 $13K
80366 936 840 $13K
80371 963 840 $12K
80325 1,133 985 $12K
80349 967 866 $11K
80355 1,080 968 $11K
80370 724 647 $11K
80361 968 868 $11K
80365 956 844 $10K
80333 667 617 $10K
80338 667 617 $10K
80357 733 650 $10K
80363 827 728 $10K
80353 905 810 $9K
80356 728 638 $8K
80321 564 508 $6K
80345 730 643 $5K
80360 487 443 $5K
80362 337 306 $4K
80369 180 149 $1K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 490 465 $232.09
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,285 1,204 $105.56
80324 15 15 $0.00